Literature DB >> 17351760

Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Vir-Singh Negi1, Sriramulu Elluru, Sophie Sibéril, Stéphanie Graff-Dubois, Luc Mouthon, Michel D Kazatchkine, Sébastien Lacroix-Desmazes, Jagadeesh Bayry, Srini V Kaveri.   

Abstract

Initially used as a replacement therapy for immunodeficiency diseases, intravenous immunoglobulin (IVIg) is now widely used for a number of autoimmune and inflammatory diseases. Considerable progress has been made in understanding the mechanisms by which IVIg exerts immunomodulatory effects in autoimmune and inflammatory disorders. The mechanisms of action of IVIg are complex, involving modulation of expression and function of Fc receptors, interference with activation of complement and the cytokine network and of idiotype network, regulation of cell growth, and effects on the activation, differentiation, and effector functions of dendritic cells, and T and B cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351760     DOI: 10.1007/s10875-007-9088-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  143 in total

1.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

2.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Authors:  D R Jayne; H Chapel; D Adu; S Misbah; D O'Donoghue; D Scott; C M Lockwood
Journal:  QJM       Date:  2000-07

3.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

4.  Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

5.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Authors:  H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens
Journal:  Ann Intern Med       Date:  2001-08-07       Impact factor: 25.391

6.  Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.

Authors:  Shiranee Sriskandan; Melissa Ferguson; Victoria Elliot; Lee Faulkner; Jonathan Cohen
Journal:  J Antimicrob Chemother       Date:  2006-05-02       Impact factor: 5.790

7.  I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome.

Authors:  M K Sharief; D A Ingram; M Swash; E J Thompson
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

8.  A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

Authors:  Erik Letko; Elisabetta Miserocchi; Yassine J Daoud; William Christen; C Stephen Foster; A Razzaque Ahmed
Journal:  Clin Immunol       Date:  2004-06       Impact factor: 3.969

9.  Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.

Authors:  A Norrby-Teglund; R Kaul; D E Low; A McGeer; D W Newton; J Andersson; U Andersson; M Kotb
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

Review 10.  Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on.

Authors:  P Bierling; B Godeau
Journal:  Vox Sang       Date:  2004-01       Impact factor: 2.144

View more
  70 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

3.  Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways.

Authors:  Kazuki Murakami; Chiaki Suzuki; Fujio Kobayashi; Atsushi Nakano; Akihiro Fujii; Kaoru Sakai; Teruaki Imada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-31       Impact factor: 3.000

Review 4.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 5.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

6.  Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis.

Authors:  Ruchi Srivastava; Chandran Ramakrishna; Edouard Cantin
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

7.  Identification of a receptor required for the anti-inflammatory activity of IVIG.

Authors:  Robert M Anthony; Fredrik Wermeling; Mikael C I Karlsson; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

8.  Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se.

Authors:  Yan Su; Robert Rossi; Anne S De Groot; David W Scott
Journal:  J Leukoc Biol       Date:  2013-05-31       Impact factor: 4.962

9.  Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.

Authors:  Parvathi Ranganathan; Hao Chen; Miranda K Adelman; Samuel F Schluter
Journal:  J Neuroimmunol       Date:  2009-10-30       Impact factor: 3.478

10.  Severe Case of Autoimmune Thrombocytopenia First Diagnosed in Pregnancy.

Authors:  K Bolten; A Salama; A Thomas; J Eucker; W Henrich
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.